Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022002781 - COMPOUNDS TARGETING ALPHA4-BETA7 1NTEGRIN

Publication Number WO/2022/002781
Publication Date 06.01.2022
International Application No. PCT/EP2021/067469
International Filing Date 25.06.2021
IPC
C07K 7/56 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
50Cyclic peptides containing at least one abnormal peptide link
54with at least one abnormal peptide link in the ring
56the cyclisation not occurring through 2,4-diamino-butanoic acid
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 31/18 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Applicants
  • ZEALAND PHARMA A/S [DK]/[DK]
Inventors
  • ROUGHTON, Andrew
  • PATEL, Narendrakumar
  • KAFAL, Adam Paul
  • VAZQUEZ, Manuel Perez
  • HICKEY, Jennifer
  • CHAKKA, Sai Kumar
  • MORSHED, Monzur
Agents
  • DUNCAN, Garreth
Priority Data
20182792.029.06.2020EP
21157715.017.02.2021EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS TARGETING ALPHA4-BETA7 1NTEGRIN
(FR) COMPOSÉS CIBLANT L'ALPHA4-BETA7 INTÉGRINE
Abstract
(EN) Compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are α4β7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.
(FR) L'invention concerne des composés de formule (I) et des sels et solvates pharmaceutiquement acceptables de ceux-ci. Les composés sont des antagonistes de α4β7 et sont utiles dans la prévention ou le traitement d'états inflammatoires et/ou de maladies auto-immunes, en particulier d'une maladie intestinale inflammatoire.
Latest bibliographic data on file with the International Bureau